Skip to the main content

Review article

Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology

Zvjezdana Špacir Prskalo orcid id orcid.org/0000-0002-4519-8183 ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mihaela Gaće ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sanja Dobrijević ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ljiljana Mayer ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia


Full text: english pdf 154 Kb

page 9-14

downloads: 459

cite


Abstract

Ovarian cancer is, with its high incidence and mortality, a worldwide problem. One reason for this is the lack of symptoms. The second reason is practically non-existant screening for ovarian cancer. Until recently, the only routinely used marker for ovarian abnormalities was CA125. Determination of HE4 levels, together with those of CA125 and the
calculation of the ROMA index, is a suitable method for improving primary detection of ovarian cancer. The measurement of serum HE4 is a useful method for diff erential diagnosis between benign gynecologic disease and ovarian cancer.

Keywords

ovarian cancer; CA125; HE4 (Human epidydimis protein); ROMA (Risk of Ovarian Malignancy Algorithm) index

Hrčak ID:

189799

URI

https://hrcak.srce.hr/189799

Publication date:

10.12.2015.

Article data in other languages: croatian

Visits: 1.648 *